Canaccord lowered the firm’s price target on Health Catalyst (HCAT) to $9 from $10 and keeps a Buy rating on the shares. The firm said while they are lowering their 2Q estimates, their 2025 forecasts are only modestly tweaked. Clearly, there remains uncertainty given the macro environment, but managementindicated confidence in a growing pipeline of new business opportunities to reach its bookings target.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HCAT:
- Health Catalyst’s Strong Financial Performance and Growth Prospects Justify Buy Rating
- Health Catalyst’s Strong Q1 Performance and Strategic Platform Transition Justify Buy Rating
- Health Catalyst Reports Strong Q1 2025 Results
- Health Catalyst: Strong Q1 Performance and Promising Growth Outlook Drive Buy Rating
- Health Catalyst reports Q1 adjusted EPS 1c, consensus 0c